Developer docs
API playgroundTry for free, no card

Search company profiles

Valeritas

Full company profile

uuid0005zdf

Namestring
Valeritas
Legal namestring
Valeritas, Inc.
Websiteurl
valeritas.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Valeritas is a commercial-stage medical technology company headquartered in Bridgewater, New Jersey, with manufacturing and R&D operations in Shrewsbury, Massachusetts. The company develops and commercializes the V-Go Disposable Insulin Delivery Device, a wearable, fully disposable, non-electronic basal-bolus insulin system worn for 24-hour cycles that delivers a preset continuous basal rate (20, 30 or 40 units per day) plus on-demand bolus dosing in 2-unit increments. V-Go received FDA 510(k) clearance and CE marking, and was launched commercially in the United States in 2012; it is sold through authorized pharmaceutical distributors including AmerisourceBergen, Cardinal Health and McKesson, with regional partners in Australia, New Zealand and Italy.

Valeritas's primary customer is the adult Type 2 diabetes patient requiring insulin therapy — a population the company estimates at roughly 5.7 million people in the United States — with prescribing driven through endocrinologists, primary care physicians and diabetes educators. The company operates a sales-led, distributor-mediated hardware-sales model, selling single-use devices through wholesalers to healthcare providers. Its broader technology portfolio includes the h-Patch subcutaneous delivery platform and the next-generation V-Go PreFill (prefilled cartridge) and V-Go Link (Bluetooth telemetry) variants currently in development; non-core assets including the Mini-Ject needle-free injector and Micro-Trans microneedle patch are being divested.

The company is publicly traded (formerly NASDAQ: VLRX, currently OTC Markets: VLRXQ), employs 101–250 people, and has cumulatively raised an estimated $355 million in private and structured financing from investors including Welsh Carson Anderson & Stowe, MPM Capital, Kaiser Permanente Ventures, Abingworth, Advanced Technology Ventures, ONSET Ventures, Pitango VC and CRG.

Short descriptiontext

Valeritas is a public medical technology company that develops and commercializes V-Go, a non-electronic disposable wearable insulin delivery device providing basal-bolus therapy for adults with Type 2 diabetes in the US, EU and select international markets via pharmaceutical wholesalers and regional distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBridgewater, United States
HQ citystring
Bridgewater
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
insulin delivery devices, disposable insulin pumps, wearable medical devices, subcutaneous drug delivery, diabetes management technology
Industry2 codes
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAG
Insulin Pumps & Patch Pumps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Insulin Delivery Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1V-Go Disposable Insulin Delivery Device Sales
TypeHardware Sales
Description

Valeritas generates revenue from the sale of V-Go Disposable Insulin Delivery devices. V-Go is a wearable, fully disposable device worn for 24 hours and then replaced. The company sells through authorized pharmaceutical distributors and directly to healthcare providers. Commercialized in the United States since 2012, with regulatory clearance in the US and EU.

valeritas.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1V-Go
Description

V-Go Disposable Insulin Delivery Device - a small, discreet and easy-to-use wearable insulin device for adults with Type 2 diabetes.

valeritas.com
+3 more records
Core offering1 text field

Valeritas develops, manufactures, and commercializes the V-Go Disposable Insulin Delivery Device, a wearable, fully disposable basal-bolus insulin delivery system worn for 24 hours that provides continuous preset basal insulin delivery and on-demand bolus dosing. The company also markets the h-Patch controlled-delivery technology platform for subcutaneous drug administration and the non-core Mini-Ject needle-free injection system and Micro-Trans microneedle array patch, while developing next-generation V-Go PreFill and V-Go Link variants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • V-Go has consistently shown to lower A1Cs with less insulin in numerous real-world analyses
+1 more record
Product overview1 text field

Valeritas is a commercial-stage medical technology company offering a portfolio of drug delivery products focused on improving health and simplifying life for people with Type 2 diabetes. The core product is V-Go, a wearable disposable insulin delivery device providing basal-bolus insulin therapy. The product line includes next-generation V-Go variants (PreFill with prefilled insulin cartridges and Link with Bluetooth connectivity) and the h-Patch controlled delivery platform. Non-core technologies include Mini-Ject (needle-free injection system) and Micro-Trans (microneedle array patch), which the company is seeking to divest.

Product and service6 records
1V-Go Disposable Insulin Delivery Device
CategoryInsulin Delivery Device
Description

A small, discreet, and easy-to-use wearable insulin delivery device that adheres to the skin every 24 hours. V-Go delivers continuous preset basal insulin (20, 30, or 40 Units per 24-hour period) and provides on-demand bolus dosing in 2 Unit increments for meals and snacks. It is FDA cleared and CE marked, and has demonstrated A1C reductions with less insulin in numerous real-world analyses for adults with Type 2 diabetes requiring insulin therapy.

2V-Go PreFill
CategoryInsulin Delivery Device
Description

Next-generation single-use disposable V-Go variant with a prefilled insulin cartridge that snaps into the device, eliminating the patient insulin-filling process to make insulin therapy even simpler for broader HCP and patient adoption. Under development.

3V-Go Link
CategoryInsulin Delivery Device
Description

Next-generation single-use disposable V-Go variant featuring one-way communication to smart devices (phones and tablets) via RF/Bluetooth technology, providing real-time tracking of basal and bolus dosing utilization to give patients and HCPs deeper insight into dosing habits. Under development.

4h-Patch Controlled Delivery Technology Platform
CategoryDrug Delivery Technology Platform
Description

A simple-to-use, fully disposable controlled delivery technology platform designed to deliver drugs into subcutaneous tissue. It combines the user advantages of transdermal patches with the accuracy and flexibility of conventional ambulatory pumps, and can accommodate pre-filled liquid or point-of-care fill for lyophilized medications.

5Mini-Ject Needle-Free Injection System
CategoryNeedle-Free Injection System
Description

A next-generation needle-free injection system combining fully disposable pre-filled options with comfortable administration. Capable of delivering a wide range of drugs from small molecules to large proteins, fragile antibodies, and vaccines, with delivery targeted to intradermal, subcutaneous, or intramuscular tissue depending on therapeutic need. Non-core technology being divested.

6Micro-Trans Microneedle Array Patch
CategoryMicroneedle Drug Delivery
Description

Microneedle Array Patch technology enabling drug delivery into the dermis without limitations of drug size, structure, charge, or patient skin characteristics. Arrays penetrate only shallow layers of skin to avoid pain receptors for patient comfort. Non-core technology being divested by Valeritas.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

AmerisourceBergen Corporation is an Authorized Distributor of Record for Valeritas, Inc. This designation identifies an ongoing relationship where the distributor is authorized to distribute the full line of Valeritas products. The distribution authorization was formalized following FDA regulations issued June 9, 2006 to strengthen protections against counterfeit drugs.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

ANDA, Inc. is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Cardinal Health is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

4McKesson Corporation
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

McKesson Corporation is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

valeritas.com
5HD Smith Wholesale Drug Company
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

HD Smith Wholesale Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

valeritas.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Burlington Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Dakota Drug is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Morris & Dickson Co., LLC is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

N.C. Mutual Wholesale Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Prescription Supply, Inc. is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Rochester Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Smith Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Value Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

14Frank W. Kerr
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Frank W. Kerr is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

valeritas.com
15Miami-Luken, Inc
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-06-09
Description

Miami-Luken, Inc is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.

valeritas.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

AMSL is the regional distributor for Valeritas products in Australia and New Zealand. Located at 2 McCabe Place, Chatswood NSW 2067, Australia. Contact: 1300 851 056.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

NZ Scientific & Medical Ltd is a regional distributor for Valeritas products in New Zealand. Located at Mt Wellington, Auckland 1060.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Movi SpA is the regional distributor for Valeritas products in Italy. Located at Via Dione Cassio 15, I - 20138, Milan, Italy.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insulet's OmniPod is a tubeless, wearable patch insulin pump for people with diabetes. It is the closest direct competitor to V-Go in the disposable/wearable insulin delivery category and targets the same patient population.

TypeBroad incumbent
Description

Medtronic's MiniMed insulin pumps, including the 780G AID system, are a long-established incumbent in insulin delivery with integrated CGM. It competes with V-Go for endocrinologist prescriptions and payor formulary slots, especially in Type 1 and insulin-requiring Type 2 patients.

TypeDirect peer
Description

Tandem sells the t:slim X2 insulin pump with Control-IQ AID technology and competes head-to-head with V-Go for patients seeking pump therapy. It shares the same endocrinologist and diabetes educator call points.

TypeDirect peer
Description

CeQur develops a wearable, disposable insulin delivery patch (PaQ) for people with Type 2 diabetes. It targets the same simple, multi-day-wear use case as V-Go, making it the most direct niche competitor in patch-meal-bolus delivery.

TypeBroad incumbent
Description

Dexcom is the leading continuous glucose monitor (CGM) provider and increasingly part of integrated pump+CGM diabetes management. While not a direct pump competitor, its dominance shapes the standard of care against which V-Go is prescribed.

TypeBroad incumbent
Description

Abbott's FreeStyle Libre is the leading CGM used by people with diabetes globally. As CGM-AID integration becomes standard, Libre sets the monitoring benchmark against which insulin delivery devices like V-Go are evaluated.

7Bigfoot Biomedical
TypeEmerging player
Description

Bigfoot is developing a connected insulin delivery system focused on Type 1 and insulin-requiring Type 2 diabetes. It targets the same simplification-for-the-patient value proposition that V-Go pitches, but with a CGM-integrated, smart-pen/pump hybrid.

TypeEmerging player
Description

MannKind commercializes Afrezza, an inhaled insulin, and is developing additional endocrine delivery technologies. While delivery modality differs, MannKind competes with Valeritas for share of voice in simplifying insulin therapy for Type 2 diabetes patients reluctant to inject.

TypeBroad incumbent
Description

Roche offers Accu-Chek insulin pumps and broader diabetes management products internationally. It competes with V-Go in select European markets where Roche's established payor relationships could limit V-Go adoption.

TypeOthers
Description

Novo Nordisk dominates the global insulin and GLP-1 market and is investing in connected pen and patch delivery devices. As a supplier of the insulin used in V-Go and a future potential competitor in patch delivery, it is an adjacent and ecosystem-defining peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valeritas

Insulin Delivery Devicesvaleritas.com

Valeritas is a public medical technology company that develops and commercializes V-Go, a non-electronic disposable wearable insulin delivery device providing basal-bolus therapy for adults with Type 2 diabetes in the US, EU and select international markets via pharmaceutical wholesalers and regional distributors.

What Valeritas does

Valeritas is a commercial-stage medical technology company headquartered in Bridgewater, New Jersey, with manufacturing and R&D operations in Shrewsbury, Massachusetts. The company develops and commercializes the V-Go Disposable Insulin Delivery Device, a wearable, fully disposable, non-electronic basal-bolus insulin system worn for 24-hour cycles that delivers a preset continuous basal rate (20, 30 or 40 units per day) plus on-demand bolus dosing in 2-unit increments. V-Go received FDA 510(k) clearance and CE marking, and was launched commercially in the United States in 2012; it is sold through authorized pharmaceutical distributors including AmerisourceBergen, Cardinal Health and McKesson, with regional partners in Australia, New Zealand and Italy.

Valeritas's primary customer is the adult Type 2 diabetes patient requiring insulin therapy — a population the company estimates at roughly 5.7 million people in the United States — with prescribing driven through endocrinologists, primary care physicians and diabetes educators. The company operates a sales-led, distributor-mediated hardware-sales model, selling single-use devices through wholesalers to healthcare providers. Its broader technology portfolio includes the h-Patch subcutaneous delivery platform and the next-generation V-Go PreFill (prefilled cartridge) and V-Go Link (Bluetooth telemetry) variants currently in development; non-core assets including the Mini-Ject needle-free injector and Micro-Trans microneedle patch are being divested.

The company is publicly traded (formerly NASDAQ: VLRX, currently OTC Markets: VLRXQ), employs 101–250 people, and has cumulatively raised an estimated $355 million in private and structured financing from investors including Welsh Carson Anderson & Stowe, MPM Capital, Kaiser Permanente Ventures, Abingworth, Advanced Technology Ventures, ONSET Ventures, Pitango VC and CRG.

Valeritas firmographics

Firmographics
Name
Valeritas
Legal name
Valeritas, Inc.
Website
https://valeritas.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Valeritas is a public medical technology company that develops and commercializes V-Go, a non-electronic disposable wearable insulin delivery device providing basal-bolus therapy for adults with Type 2 diabetes in the US, EU and select international markets via pharmaceutical wholesalers and regional distributors.
Ownership category
akta.pro rank

Valeritas industry classification

Industry
Product category
Insulin Delivery Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAG
Insulin Pumps & Patch Pumps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Insulin delivery devices
  • Disposable insulin pumps
  • Wearable medical devices
  • Subcutaneous drug delivery
  • Diabetes management technology

Where Valeritas is headquartered

Location

Headquarters

HQ city
Bridgewater
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Valeritas business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. V-Go Disposable Insulin Delivery Device Sales: Valeritas generates revenue from the sale of V-Go Disposable Insulin Delivery devices. V-Go is a wearable, fully disposable device worn for 24 hours and then replaced. The company sells through authorized pharmaceutical distributors and directly to healthcare providers. Commercialized in the United States since 2012, with regulatory clearance in the US and EU.

Go-to-market motion1 record

Distribution channels9 records

Marketing channels6 records

Valeritas product offering

Product offering

Core offering

Valeritas develops, manufactures, and commercializes the V-Go Disposable Insulin Delivery Device, a wearable, fully disposable basal-bolus insulin delivery system worn for 24 hours that provides continuous preset basal insulin delivery and on-demand bolus dosing. The company also markets the h-Patch controlled-delivery technology platform for subcutaneous drug administration and the non-core Mini-Ject needle-free injection system and Micro-Trans microneedle array patch, while developing next-generation V-Go PreFill and V-Go Link variants.

Product overview

Valeritas is a commercial-stage medical technology company offering a portfolio of drug delivery products focused on improving health and simplifying life for people with Type 2 diabetes. The core product is V-Go, a wearable disposable insulin delivery device providing basal-bolus insulin therapy. The product line includes next-generation V-Go variants (PreFill with prefilled insulin cartridges and Link with Bluetooth connectivity) and the h-Patch controlled delivery platform. Non-core technologies include Mini-Ject (needle-free injection system) and Micro-Trans (microneedle array patch), which the company is seeking to divest.

Differentiator

Problem solved

Functional benefit

Brands

  • V-Go: V-Go Disposable Insulin Delivery Device - a small, discreet and easy-to-use wearable insulin device for adults with Type 2 diabetes.
  • h-Patch
  • Mini-Ject
  • Micro-Trans

Products and services

  • V-Go Disposable Insulin Delivery Device A small, discreet, and easy-to-use wearable insulin delivery device that adheres to the skin every 24 hours. V-Go delivers continuous preset basal insulin (20, 30, or 40 Units per 24-hour period) and provides on-demand bolus dosing in 2 Unit increments for meals and snacks. It is FDA cleared and CE marked, and has demonstrated A1C reductions with less insulin in numerous real-world analyses for adults with Type 2 diabetes requiring insulin therapy.
  • V-Go PreFill Next-generation single-use disposable V-Go variant with a prefilled insulin cartridge that snaps into the device, eliminating the patient insulin-filling process to make insulin therapy even simpler for broader HCP and patient adoption. Under development.
  • V-Go Link Next-generation single-use disposable V-Go variant featuring one-way communication to smart devices (phones and tablets) via RF/Bluetooth technology, providing real-time tracking of basal and bolus dosing utilization to give patients and HCPs deeper insight into dosing habits. Under development.
  • h-Patch Controlled Delivery Technology Platform A simple-to-use, fully disposable controlled delivery technology platform designed to deliver drugs into subcutaneous tissue. It combines the user advantages of transdermal patches with the accuracy and flexibility of conventional ambulatory pumps, and can accommodate pre-filled liquid or point-of-care fill for lyophilized medications.
  • Mini-Ject Needle-Free Injection System A next-generation needle-free injection system combining fully disposable pre-filled options with comfortable administration. Capable of delivering a wide range of drugs from small molecules to large proteins, fragile antibodies, and vaccines, with delivery targeted to intradermal, subcutaneous, or intramuscular tissue depending on therapeutic need. Non-core technology being divested.
  • Micro-Trans Microneedle Array Patch Microneedle Array Patch technology enabling drug delivery into the dermis without limitations of drug size, structure, charge, or patient skin characteristics. Arrays penetrate only shallow layers of skin to avoid pain receptors for patient comfort. Non-core technology being divested by Valeritas.

Quantifiable outcome

  • V-Go has consistently shown to lower A1Cs with less insulin in numerous real-world analyses
  • +1 more outcomes

Companies that use Valeritas

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Valeritas technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Valeritas partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core.

  • AmerisourceBergen CorporationcoreChannel Partner/ Reseller/ Distributor · 9 June 2006AmerisourceBergen Corporation is an Authorized Distributor of Record for Valeritas, Inc. This designation identifies an ongoing relationship where the distributor is authorized to distribute the full line of Valeritas products. The distribution authorization was formalized following FDA regulations issued June 9, 2006 to strengthen protections against counterfeit drugs.
  • ANDA, Inc.coreChannel Partner/ Reseller/ Distributor · 9 June 2006ANDA, Inc. is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Cardinal HealthcoreChannel Partner/ Reseller/ Distributor · 9 June 2006Cardinal Health is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • McKesson CorporationcoreChannel Partner/ Reseller/ Distributor · 9 June 2006McKesson Corporation is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • HD Smith Wholesale Drug CompanycoreChannel Partner/ Reseller/ Distributor · 9 June 2006HD Smith Wholesale Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Burlington Drug CompanycoreChannel Partner/ Reseller/ Distributor · 9 June 2006Burlington Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Dakota DrugcoreChannel Partner/ Reseller/ Distributor · 9 June 2006Dakota Drug is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Morris & Dickson Co., LLCcoreChannel Partner/ Reseller/ Distributor · 9 June 2006Morris & Dickson Co., LLC is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • N.C. Mutual Wholesale Drug CompanycoreChannel Partner/ Reseller/ Distributor · 9 June 2006N.C. Mutual Wholesale Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Prescription Supply, Inc.coreChannel Partner/ Reseller/ Distributor · 9 June 2006Prescription Supply, Inc. is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Rochester Drug CompanycoreChannel Partner/ Reseller/ Distributor · 9 June 2006Rochester Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Smith Drug CompanycoreChannel Partner/ Reseller/ Distributor · 9 June 2006Smith Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Value Drug CompanycoreChannel Partner/ Reseller/ Distributor · 9 June 2006Value Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Frank W. KerrcoreChannel Partner/ Reseller/ Distributor · 9 June 2006Frank W. Kerr is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Miami-Luken, InccoreChannel Partner/ Reseller/ Distributor · 9 June 2006Miami-Luken, Inc is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
  • Australasian Medical & Scientific (AMSL)coreChannel Partner/ Reseller/ DistributorAMSL is the regional distributor for Valeritas products in Australia and New Zealand. Located at 2 McCabe Place, Chatswood NSW 2067, Australia. Contact: 1300 851 056.
  • NZ Scientific & Medical LtdcoreChannel Partner/ Reseller/ DistributorNZ Scientific & Medical Ltd is a regional distributor for Valeritas products in New Zealand. Located at Mt Wellington, Auckland 1060.
  • Movi SpAcoreChannel Partner/ Reseller/ DistributorMovi SpA is the regional distributor for Valeritas products in Italy. Located at Via Dione Cassio 15, I - 20138, Milan, Italy.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Valeritas competitors and assessment

Company assessment

Direct peers

  • Insulet Corporation: Insulet's OmniPod is a tubeless, wearable patch insulin pump for people with diabetes. It is the closest direct competitor to V-Go in the disposable/wearable insulin delivery category and targets the same patient population.
  • Tandem Diabetes Care: Tandem sells the t:slim X2 insulin pump with Control-IQ AID technology and competes head-to-head with V-Go for patients seeking pump therapy. It shares the same endocrinologist and diabetes educator call points.
  • CeQur: CeQur develops a wearable, disposable insulin delivery patch (PaQ) for people with Type 2 diabetes. It targets the same simple, multi-day-wear use case as V-Go, making it the most direct niche competitor in patch-meal-bolus delivery.

Broad incumbents

  • Medtronic (Diabetes): Medtronic's MiniMed insulin pumps, including the 780G AID system, are a long-established incumbent in insulin delivery with integrated CGM. It competes with V-Go for endocrinologist prescriptions and payor formulary slots, especially in Type 1 and insulin-requiring Type 2 patients.
  • Dexcom: Dexcom is the leading continuous glucose monitor (CGM) provider and increasingly part of integrated pump+CGM diabetes management. While not a direct pump competitor, its dominance shapes the standard of care against which V-Go is prescribed.
  • Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre is the leading CGM used by people with diabetes globally. As CGM-AID integration becomes standard, Libre sets the monitoring benchmark against which insulin delivery devices like V-Go are evaluated.
  • Roche Diabetes Care: Roche offers Accu-Chek insulin pumps and broader diabetes management products internationally. It competes with V-Go in select European markets where Roche's established payor relationships could limit V-Go adoption.

Emerging players

  • Bigfoot Biomedical: Bigfoot is developing a connected insulin delivery system focused on Type 1 and insulin-requiring Type 2 diabetes. It targets the same simplification-for-the-patient value proposition that V-Go pitches, but with a CGM-integrated, smart-pen/pump hybrid.
  • MannKind Corporation: MannKind commercializes Afrezza, an inhaled insulin, and is developing additional endocrine delivery technologies. While delivery modality differs, MannKind competes with Valeritas for share of voice in simplifying insulin therapy for Type 2 diabetes patients reluctant to inject.

Others

  • Novo Nordisk (Diabetes Care Devices): Novo Nordisk dominates the global insulin and GLP-1 market and is investing in connected pen and patch delivery devices. As a supplier of the insulin used in V-Go and a future potential competitor in patch delivery, it is an adjacent and ecosystem-defining peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Valeritas social profiles

Digital presence

Valeritas financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valeritas leadership team

Management profile

Number of profiles

Profiles11 records

Valeritas funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valeritas M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valeritas

What does Valeritas do?

Valeritas develops, manufactures, and commercializes the V-Go Disposable Insulin Delivery Device, a wearable, fully disposable basal-bolus insulin delivery system worn for 24 hours that provides continuous preset basal insulin delivery and on-demand bolus dosing. The company also markets the h-Patch controlled-delivery technology platform for subcutaneous drug administration and the non-core Mini-Ject needle-free injection system and Micro-Trans microneedle array patch, while developing next-generation V-Go PreFill and V-Go Link variants.

Is Valeritas a public or private company?

Valeritas is a public company. It is classified as public and is currently operating.

When was Valeritas founded?

Valeritas was founded in 2006. It employs 11 to 50 people.

Where is Valeritas based?

Valeritas is headquartered in Bridgewater, United States, in the North America region.

How does Valeritas make money?

One revenue line is on record: V-Go Disposable Insulin Delivery Device Sales.

Who are Valeritas's main competitors?

Direct peers on record are Insulet Corporation, Tandem Diabetes Care and CeQur. Broad incumbents are Medtronic (Diabetes), Dexcom, Abbott Diabetes Care (FreeStyle Libre) and Roche Diabetes Care. Emerging players are Bigfoot Biomedical and MannKind Corporation. Novo Nordisk (Diabetes Care Devices) is listed as an others.

Does Valeritas have an API?

No public API is recorded for Valeritas.

What industry is Valeritas in?

Valeritas's product category is Insulin Delivery Devices. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery, with a secondary code of HLAHAIAG, Insulin Pumps & Patch Pumps. Its NAICS code is 3391 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Markets DailyValeritas (OTCMKTS:VLRXQ) & IceCure Medical (NASDAQ:ICCM) Head-To-Head ContrastMarketBeat conducted a comparative analysis of healthcare companies IceCure Medical and Valeritas, evaluating metrics such as earnings, valuation, analyst recommendations, and profitability. The report concluded that IceCure Medical is the superior business based on six out of nine compared factors, despite both companies currently operating at a loss.Defense WorldValeritas (OTCMKTS:VLRXQ) and Bio-Rad Laboratories (NYSE:BIO) Financial ReviewThis article compares the financial profiles of Valeritas (OTCMKTS:VLRXQ) and Bio-Rad Laboratories (NYSE:BIO), two medical technology companies, across metrics including revenue, earnings, valuation, profitability, and analyst ratings.openPR.comNeedle Free Injection Systems Market Is Going to Boom Rapidly With Top Key Players InsuJet • Acelity • Valeritas • InjexThe article discusses the rapid growth forecast for the needle free injection systems market from 2026 to 2033, emphasizing key companies involved in the industry. It highlights market trends, drivers, challenges, and strategic insights for industry stakeholders.Plastics TodayWearable insulin-delivery device uses COC polymer from TopasValeritas Holdings Inc. utilizes cyclic olefin copolymer (COC) from Topas Advanced Polymers in the injection-molded cartridges of its V-Go wearable insulin delivery device for Type 2 diabetes patients. The material was selected for its purity, drug compatibility, and dimensional stability, enabling the device to preserve long-term drug integrity while offering users a reduction in daily insulin usage by up to 44%.PR NewswireGlobal Insulin Patch Pumps Market Report 2022-2026 & 2031 - Integration with Smartphones and Enabling Automation Gaining TractionThe global insulin patch pumps market is projected to grow from $1.10 billion in 2021 to $1.63 billion by 2026, driven by the rising prevalence of diabetes affecting approximately 537 million people in 2021. Insulet Corporation received FDA clearance in January 2022 for its Omnipod 5 automated insulin delivery system, the first tubeless system with smartphone control. Zealand Pharma acquired Valeritas for $23 million in April 2020 to expand its footprint in the US diabetes market and gain access to the V-Go wearable insulin delivery device.PR NewswireGlobal Wearable Injectors Market Research Report 2021 Featuring Amgen, BD & Co., Enable Injections, Insulet, Ypsomed, Medtronic, Tandem Diabetes Care, Valeritas, West Pharma Services & Sensile MedicalResearch and Markets has published a report on the global wearable injectors market, projecting growth from $5.145 billion in 2020 to $5.709 billion in 2021 at an 11% CAGR. The market is driven by rising chronic disease prevalence and companies resuming operations post-pandemic, though high device costs remain a restraint. Key industry players include Amgen, Medtronic, Insulet Corporation, and Valeritas, with recent consolidation activity such as Zealand Pharma's acquisition of Valeritas.PR NewswireValeritas Receives Court Approval of Sale of Business to Zealand PharmaThe U.S. Bankruptcy Court for the District of Delaware approved the sale of substantially all of Valeritas Holdings, Inc.'s business to Zealand Pharma A/S. The transaction is anticipated to close in early April 2020, with Zealand expected to retain most of Valeritas' employees and continue the commercialization of its V-Go® device.PR NewswireValeritas Announces Agreement for Zealand Pharma to Acquire Business and Retain EmployeesValeritas Holdings, Inc., a commercial-stage medical technology company and maker of the V-Go® Wearable Insulin Delivery device, has announced an agreement to sell substantially all of its business to Zealand Pharma A/S for $23 million in cash consideration, including the assumption of certain liabilities. The transaction is being executed through a voluntary Chapter 11 bankruptcy filing in the U.S. Bankruptcy Court for the District of Delaware, with a stalking horse asset purchase agreement and competitive bidding process under Section 363 of the Bankruptcy Code. Zealand Pharma, a Denmark-based biotechnology company, intends to continue Valeritas' commercially-focused operations and retain nearly all Valeritas employees, positioning to build a commercial competitor in the U.S. diabetes market.GlobeNewswireValeritas Experiences a Temporary Supply Disruption Resulting in Revised Preliminary Financial Results for 2019 Fourth Quarter and Full YearValeritas Holdings revised its Q4 2019 revenue guidance to $8.0–8.2 million and full-year to $30.2–30.4 million due to a manufacturing yield issue causing supply disruption. The company expects a one-time inventory write-off up to $8 million and a negative gross margin for Q4. It has engaged Lincoln International to explore strategic alternatives, including a sale or Chapter 11 process.PR Newswire$3 Bn Diabetes Management Insulin Pumps Market, 2022ResearchAndMarkets has published a market report valued at nearly $3 billion in 2017, showing the insulin pumps market growing at approximately 10% annually, driven by rising global diabetes prevalence projected to increase from 425 million to 629 million adults by 2045. The market is being shaped by technological innovation, particularly Medtronic's launch of the MiniMed 670G as the world's first hybrid closed-loop insulin pump (artificial pancreas), with other competitors including Insulet, Tandem Diabetes Care, Roche, and Valeritas gaining market share. Over the next 2–5 years, emerging players such as Beta Bionics, Bigfoot Biomedical, Diabeloop, and Senseonics developing next-generation artificial pancreas systems may intensify competition and potentially threaten Medtronic's dominant market position.